Optimization of Pathologists’ Roles in Molecular Biomarker Testing in Metastatic Breast Cancer

More than 4 million women are living with breast cancer in the United States, with approximately 170,000 cases of metastatic breast cancer (mBC).1 Although the mortality rate has decreased by 44% between 1989 and 2022 because of advances in treatment and screening, there is a need to further improve outcomes through expanding access to therapies.2,3